Potent LXR agonist (IC50
values are 24 and 179 nM for LXRβ
, respectively). Reduces total serum cholesterol and LDL cholesterol, and inhibits lesion growth in models of atherosclerosis. Increases ABCA1 and ABCG1 mRNA levels in rat peripheral blood cells. Orally bioavailable.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from Pfizer Inc.
Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells.
DiBlasio-Smith et al.
LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse.
Quinet et al.
J.Lipid Res., 2009;50:2358